Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) announced that the Japan Patent Office granted Japanese Patent No. 7797537 on March 12, 2026, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis."
The patent, originally registered December 26, 2025, contains 34 claims covering the Co-Dx PCR Pro instrument, proprietary test cups, and core automated point-of-care PCR platform technologies, and follows a 2025 Australian patent. The company says this expands international IP protection while the platform remains subject to regulatory review and is not yet for sale.
Positive
- Japan patent granted (No. 7797537) strengthens IP
- 34 patent claims cover instrument and test cups
- Expands international portfolio after 2025 Australian patent
Negative
- Co-Dx PCR platform remains subject to regulatory review and not for sale
News Market Reaction – CODX
In the Mar 12 session, CODX declined 18.83%, reflecting a significant negative market reaction. Argus tracked a peak move of +31.0% during that session. Argus tracked a trough of -15.0% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Nasdaq compliance regained | Positive | +101.8% | Regained compliance with Nasdaq listing and $1.00 bid price requirement. |
| Feb 09 | Expo participation | Positive | -4.7% | Showcasing PCR platform at Dubai health expo and highlighting MENA joint venture. |
| Feb 05 | India instrument license | Positive | +0.0% | CoSara received CDSCO license to manufacture and sell PCR Pro instrument in India. |
| Feb 04 | ISO certification | Positive | +0.0% | CoSara obtained ISO 13485:2016 certification for its India manufacturing facility. |
| Jan 12 | Distributor expansion | Positive | -3.4% | CoSara expanded distributor engagement and prepared for MTB test clinical studies. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and regulatory updates often saw flat or negative price reactions, with the Nasdaq compliance win on Mar 10, 2026 a notable upside outlier.
Over the past few months, Co-Diagnostics has focused on advancing and positioning its Co-Dx PCR platform globally. On Jan 12, 2026, its CoSara JV highlighted distributor expansion and preparation for clinical studies. In early February, CoSara obtained ISO 13485 certification and an Indian CDSCO license tied to the PCR Pro instrument, plus a Dubai expo appearance. On Mar 10, 2026, the company regained Nasdaq listing compliance, which was followed by a strong positive share move. Today’s Japanese patent further extends this platform-focused trajectory and international positioning.
Key Terms
polymerase chain reaction (pcr) medical
point-of-care medical
patent cooperation treaty (pct) regulatory
molecular diagnostics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initially registered on December 26, 2025, the patent includes 34 claims and was filed under the Patent Cooperation Treaty (PCT) to allow the Company to pursue coordinated international protection in countries around the world with a single application.
"The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "We believe that receiving such a comprehensive patent by the JPO illustrates the uniqueness and innovation of the Co-Dx platform, and its potential for transforming how and where infectious diseases are diagnosed. This patent reinforces the global protection of our platform technologies and supports our strategy to expand access to affordable, high-performance point-of-care PCR testing solutions worldwide."
The issuance follows the patent granted by the Australian Patent Office in 2025 and further expands the Company's growing patent portfolio, which is designed to protect the Co-Dx PCR platform and associated technologies in key international markets. By securing intellectual property rights in
Co-Diagnostics' Co-Dx PCR point-of-care system is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments. The platform leverages the Company's patented Co-Primers® technology and aims to enable rapid, sensitive, and specific molecular diagnostics across a broad range of applications.
The 34 claims in the patent cover the fundamental systems, methods, and apparatus for automated, self-contained biological analysis performed by Co-Dx's PCR platform, and encompasses both the Co-Dx instrument and its proprietary test cups designed for use with the system.
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believes," "expects," "anticipates," "intends," "plans," "may," "will," "potential," "could," and similar expressions, or the negative of these terms. These statements include, but are not limited to, statements regarding the potential applications, capabilities, regulatory status, commercialization prospects, and market opportunities for the Company's Co-Dx PCR platform, including the Co-Dx PCR Pro® instrument and related technologies, as well as the potential impact of the Company's intellectual property portfolio, including recently issued patents. Forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to regulatory review and approvals, product development and validation, intellectual property protection, market acceptance of new diagnostic technologies, commercialization efforts, competition, and other risks described in the Company's filings with the Securities and Exchange Commission, including the Risk Factors section of the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and subsequent reports filed with the SEC. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-receives-japanese-patent-covering-co-dx-pcr-platform-technologies-302711784.html
SOURCE Co-Diagnostics